Idioma:

Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network

Ogdie, Alexis ; Alehashemi, Sara ; Love, Thorvardur Jon ; Jiang, Yihui ; Haynes, Kevin ; Hennessy, Sean ; Choi, Hyon ; Gelfand, Joel M.

Pharmacoepidemiology and drug safety, 2014-09, Vol.23 (9), p.918-922 [Periódico revisado por pares]

Chichester: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network
Autor: Ogdie, Alexis ; Alehashemi, Sara ; Love, Thorvardur Jon ; Jiang, Yihui ; Haynes, Kevin ; Hennessy, Sean ; Choi, Hyon ; Gelfand, Joel M.
Assuntos: Adult ; Aged ; Algorithms ; Antirheumatic Agents - therapeutic use ; Arthritis ; Arthritis, Psoriatic - diagnosis ; Arthritis, Psoriatic - drug therapy ; Biological and medical sciences ; Clinical Coding - standards ; Clinical trial. Drug monitoring ; Codes ; Cross-Sectional Studies ; Databases, Factual - statistics & numerical data ; Dermatology ; disease modifying antirheumatic drug (DMARD) ; Diseases of the osteoarticular system ; Diseases of the spine ; Drug therapy ; Electronic Health Records - statistics & numerical data ; Female ; General pharmacology ; General Practitioners ; Humans ; Inflammatory joint diseases ; Male ; Medical Records - statistics & numerical data ; Medical sciences ; Middle Aged ; pharmacoepidemiology ; Pharmacology. Drug treatments ; Predictive Value of Tests ; Psoriasis ; Psoriasis. Parapsoriasis. Lichen ; psoriatic arthritis ; Sensitivity and Specificity ; Surveys and Questionnaires ; the health improvement network ; validation
É parte de: Pharmacoepidemiology and drug safety, 2014-09, Vol.23 (9), p.918-922
Notas: Clinical and Translational Science Award at the University of Pennsylvania - No. 8UL1TR000003
ArticleID:PDS3677
American College of Rheumatology Research Foundation and NIH - No. K23AR063764; No. R01AG025152; No. R01HL111293
Supporting info item
American College of Rheumatology Research Foundation
The Icelandic Research Fund - No. 120433021.
istex:0AF945E05049F7E997172A8F9FE9AB6D1A18A59E
ark:/67375/WNG-M79S7QCB-L
This paper was presented in poster form at the International Conference on Pharmacoepidemiology in Montreal, CA, on 26 August 2013. In addition, the positive predictive value and a short summary of the methods were published in a manuscript in Rheumatology (Oxford) in 2013 (referenced below). However, the survey results have not been published. Only the following sentence from the validation study was published in the Rheumatology paper: "Among the 100 GPs of patients with a Read code for PsA selected for query, 87 surveys were returned within 90 days. Seventy-four patients (85.1%, 95% CI 75.8%, 91.7%) had a confirmed diagnosis of PsA. Among these 74 patients, 62 (83.7%) had been seen by a rheumatologist who corroborated the diagnosis."
This paper was presented in poster form at the International Conference on Pharmacoepidemiology in Montreal, CA, on 26 August 2013. In addition, the positive predictive value and a short summary of the methods were published in a manuscript in Rheumatology (Oxford) in 2013 (referenced below). However, the survey results have not been published. Only the following sentence from the validation study was published in the Rheumatology paper: “Among the 100 GPs of patients with a Read code for PsA selected for query, 87 surveys were returned within 90 days. Seventy‐four patients (85.1%, 95% CI 75.8%, 91.7%) had a confirmed diagnosis of PsA. Among these 74 patients, 62 (83.7%) had been seen by a rheumatologist who corroborated the diagnosis.”
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Descrição: ABSTRACT Purpose The aims of this study are to examine the validity of diagnostic codes for psoriatic arthritis in The Health Improvement Network (THIN) and to examine the agreement between General Practitioner (GP) report and prescription records for disease modifying antirheumatic drugs (DMARDs). Methods Questionnaires were sent to the GPs of 100 randomly selected patients with at least one medical record code for psoriatic arthritis. The positive predictive value (PPV) for a GP confirmed diagnosis was calculated, and alternative algorithms were examined to determine which method resulted in the highest PPV. Results The PPV for a single code for psoriatic arthritis was 85% (95%CI: 75.8–91.7%). Adding a prescription for a DMARD increased the PPV to 91% but with a substantial loss in sensitivity. Agreement between GPs and prescription data for use of an oral DMARD was 69%. Conclusions The diagnosis codes for psoriatic arthritis used in THIN are valid. All prescriptions for DMARDs may not be accounted for in THIN. Copyright © 2014 John Wiley & Sons, Ltd.
Editor: Chichester: Blackwell Publishing Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network

Ogdie, Alexis ; Alehashemi, Sara ; Love, Thorvardur Jon ; Jiang, Yihui ; Haynes, Kevin ; Hennessy, Sean ; Choi, Hyon ; Gelfand, Joel M.

Chichester: Blackwell Publishing Ltd

Buscando em bases de dados remotas. Favor aguardar.